|
|
|
10033
|
|
|
P.I.:
|
Joanne Mortimer, MD
|
(Industrial)
|
|
Title:
|
A Randomized, Open-Labeled, Multi-Center, Phase I, Crossover Study to Assess the Relative Bioavailability of 2 Oral Formulation of TK1258, and the Effect of Food on Bioavailability of TK1258, in Patients with Advanced Solid Tumors
|
|
|
09160
|
|
|
P.I.:
|
Sumanta Pal, MD
|
(Industrial)
|
|
Title:
|
A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Patients with CD70- Positive Relapsed or Refractory Non-Hodgkin Lymphoma or Metastatic Renal Cell Carcinoma
|
| | |
|
|
09148
|
|
|
P.I.:
|
Robert Chen, MD
|
(Industrial)
|
|
Title:
|
SGN-35-008 An Open Label Clinical Pharmacology An Open-Label Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) in Patients With CD30-Positive Hematologic Malignancies: CYP3A4 Drug-Drug Interactions, Excretion, and Special Populations
|
| | |
|
|
09120
|
|
|
P.I.:
|
Vincent Chung, MD
|
(Cooperative Group)
|
|
Title:
|
SWOG S0711: Phase I Pharmacokinetic Study of Dasatinib (BMS-354825)(NSC-732517, IND-73969) in Patients with Advanced Malignancies and Varying Levels of Liver Dysfunction
|
| | |
|
|
09119
|
|
|
P.I.:
|
Stephen Shibata, MD
|
(Industrial)
|
|
Title:
|
Phase 1b Multiple Ascending Dose Study of BMS-833923 (XL139) Administered in Combination with Cisplatin and Capecitabine as First Line Therapy in Patients with Inoperable Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas
|
| | |
|